TScan Therapeutics, Inc. (TCRX)
| Market Cap | 52.03M -46.9% |
| Revenue (ttm) | 9.14M +106.7% |
| Net Income | -124.31M |
| EPS | -2.07 |
| Shares Out | 65.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 336,330 |
| Open | 0.7542 |
| Previous Close | 0.7632 |
| Day's Range | 0.7542 - 0.8041 |
| 52-Week Range | 0.7160 - 2.5700 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 6.00 (+653.58%) |
| Earnings Date | Aug 11, 2026 |
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It ... [Read more]
Financial Performance
In 2025, TScan Therapeutics's revenue was $10.33 million, an increase of 266.65% compared to the previous year's $2.82 million. Losses were -$129.77 million, 1.78% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for TCRX stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 653.58% from the latest price.
News
TScan Therapeutics doses first patient in ALLOHA-2 trial
TScan Therapeutics (TCRX) announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2 trial. The patient, who was enrolled in June, has now received…
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
The lead T cell therapy program is advancing to phase III for post-transplant relapse prevention in heme malignancies, with strong early efficacy signals and improved manufacturing. The pivotal trial is designed for broad accessibility and regulatory rigor, with regular data updates and financial strategies in place to bridge to top-line results.
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics Transcript: KOL event
Updated phase I data show TSC-101 achieves high rates of complete donor chimerism and strong safety in difficult-to-treat post-transplant AML/MDS patients. The new manufacturing process improves efficiency, and the phase III pivotal trial is launching with broad market expansion plans.
TScan Therapeutics Press release: KOL event
TScan Therapeutics issued a press release on June 22, 2026, disclosing material business information to investors.
TScan Therapeutics Slides: KOL event
TScan Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.
TScan Therapeutics presents data from Cohort C of ALLOHA trial
TScan Therapeutics (TCRX) presented data from Cohort C of the ongoing ALLOHA Phase 1 study, evaluating TSC-101 generated with the commercial-ready manufacturing process, in patients with heme malignan...
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101
TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing
Cellares and TScan Therapeutics (TCRX) announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan’s lead TCR-T therapy candidate for patients with acute myeloid leukemia (AM...
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical...
TScan Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum, approved two director nominees, ratified Deloitte & Touche LLP as auditor, and authorized an increase in common stock. All proposals passed without stockholder questions, and results will be filed with the SEC.
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
Reports Q1 revenue $982,000, consensus $2.5M. “2026 will be a critical year for TScan as we advance our mission to deliver transformative T cell therapies to patients. We have multiple…
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™) planned for the second quarter ...
TScan Therapeutics Earnings release: Q1 2026
TScan Therapeutics released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
TScan Therapeutics Quarterly report: Q1 2026
TScan Therapeutics has published its Q1 2026 quarterly earnings report on May 6, 2026.
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics Proxy statement: Proxy filing
TScan Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
The conference highlighted a differentiated TCR T cell therapy platform targeting post-transplant AML/MDS relapse, with phase I data showing >50% relapse reduction and long-lived responses. A pivotal trial launches mid-2024, with commercial launch expected in 2029 and strong profit margins projected. Additional HLA-targeted products and an in vivo solid tumor platform are in development.
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell...
TScan Therapeutics Proxy statement: Proxy filing
TScan Therapeutics filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
TScan Therapeutics price target raised to $5 from $4 at Wedbush
Wedbush raised the firm’s price target on TScan Therapeutics (TCRX) to $5 from $4 and keeps an Outperform rating on the shares. The firm says the company reported earnings and…
TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Lead TCR T-cell therapy for heme malignancies shows strong phase I efficacy and safety, with pivotal trial launching in Q2 and commercial-ready manufacturing in place. Market expansion through additional HLA-targeted products could double the addressable patient population.
TScan Therapeutics reports Q4 EPS (18c), consensus (28c)
Reports Q4 revenue $2.6M, consensus $2.42M “The regulatory and operational progress we have made over the last several months related to our heme program is exciting. We expect the momentum…
TScan Therapeutics sees cash runway into 2H27
Cash and cash equivalents as of December 31, 2025 were $152.4 million, excluding $5.0 million of restricted cash. The Company believes that its existing cash resources will be sufficient to…